{
    "title": "110_hr3368",
    "content": "The Act may be cited as the \"Pulmonary Hypertension Research and Education Act of 2007\". The Congress recognizes pulmonary hypertension as a serious condition where blood pressure in the lungs rises to dangerous levels, leading to heart enlargement and potential failure. Federal investment in research for a cure or treatment must be expanded to fully utilize its potential. Federal investment in pulmonary hypertension research needs to be increased, along with collaboration among top research centers. Diagnosis of the disease is challenging and often goes undetected in routine medical exams. New diagnostic standards have improved detection rates. In advanced stages, patients have limited activity levels. In 1981, the National Heart, Lung, and Blood Institute established the first pulmonary hypertension patient registry, following 194 people over several years. This study has contributed significantly to our understanding of the disease, which can progress to the point of complete bedriddeness. Research studies are investigating immunologic and genetic factors in the cause of pulmonary hypertension, focusing on agents narrowing blood vessels and factors causing cell growth and scar tissue formation. Treatments for pulmonary hypertension are advancing with six FDA-approved medications available. The number of FDA-approved medications for pulmonary hypertension is increasing, but not all are effective for every patient. These treatments come with significant side effects, leading some to consider lung transplantation as a last resort. The growing number of physicians treating pulmonary hypertension highlights the need for increased medical education in this area. In 2001, there were 100 physicians treating pulmonary hypertension, with 3,000 patients receiving treatment. By 2006, the number of physicians increased to 3,000, treating 30,000 patients. Despite the availability of oral therapies, effective management of pulmonary hypertension remains complex, emphasizing the importance of educating medical professionals in this field. Education of medical professionals on pulmonary hypertension management is crucial for optimal patient care. In December 2006, the National Heart, Lung, and Blood Institute hosted a significant meeting of researchers and clinicians worldwide, emphasizing the importance of communication for future advancements in fighting this disease. The Public Health Service Act is amended to include a section on pulmonary hypertension research and training. The Director of the Institute will expand research on pulmonary hypertension and establish a Pulmonary Hypertension Clinical Research Network to conduct clinical trials for new treatment approaches. The Director of the Institute will establish a Pulmonary Hypertension Clinical Research Network to evaluate new treatment approaches for pulmonary hypertension. The network will include 15 clinical centers, an institute project scientist, a data and coordinating center, and a data and safety monitoring board appointed by the Director. The Pulmonary Hypertension Clinical Research Network will have a steering committee, principal investigators from clinical centers, a data and coordinating center, and an independent protocol review committee appointed by the Director. The Pulmonary Hypertension Clinical Research Network will conduct specific clinical trials including combination therapies, new drug therapy avenues, and the use of endothelial progenitor cells. The Pulmonary Hypertension Clinical Research Network focuses on using endothelial progenitor cells for replacing abnormal pulmonary vascular cells and discovering treatment effects predictive of long-term outcomes. The Institute manages program organization and support for the network. The Pulmonary Hypertension Clinical Research Network oversees subject recruitment, trial progress monitoring, conflict of interest disclosure, adherence to policies, and fiscal management with the Institute grants management specialist. The Director appoints the Chair of the steering committee, members of the protocol review committee, and the data safety monitoring board for the Pulmonary Hypertension Clinical Research Network. The Director will establish a grant program for a national Pulmonary Hypertension Preceptorship and Training Program to facilitate direct training. The grant program aims to train medical professionals in clinical settings to effectively diagnose, treat, and manage pulmonary hypertension, with regional training sites established for this purpose. The grant program aims to establish regional training sites at academic health centers, hospitals, or private medical practices to train medical professionals in pulmonary hypertension. Each site will have a designated contact person, with a stipend allocated from the grant funds for this purpose. The nonprofit entity awarded the grant will establish mechanisms for recruiting health professionals and setting program guidelines. Model guidelines will be developed in collaboration with regional training sites and the Institute. Authorization of appropriations is provided for fiscal years 2009 through 2012. Increasing public awareness of pulmonary hypertension. The Secretary of Health and Human Services will develop and share information on pulmonary hypertension, covering basic information, incidence, related diseases, early diagnosis importance, and available treatments. The Secretary of Health and Human Services will disseminate information on pulmonary hypertension treatment options through a national non-profit entity. Appropriations are authorized for fiscal years 2009 through 2012. The Secretary of Health and Human Services will disseminate information on pulmonary hypertension treatment options through a national non-profit entity. The Secretary of Health and Human Services will develop and distribute information on pulmonary hypertension to healthcare providers, focusing on symptoms, early diagnosis, and FDA-approved therapies. The Secretary of Health and Human Services will disseminate information on pulmonary hypertension to healthcare providers through a national non-profit entity with expertise in the field. Appropriations are authorized for fiscal years 2009 through 2012. The Government Accountability Office will conduct a study on Medicare and Medicaid coverage standards. The Comptroller General will conduct a study on Medicare and Medicaid coverage standards for individuals with pulmonary hypertension, including all FDA-approved therapies. The study will consider outpatient or home health care settings for service delivery. A report must be submitted to Congress within six months of the Act's enactment. Upon enactment of this Act, the Comptroller General will submit a report to Congress detailing the findings of the study on Medicare and Medicaid coverage standards for individuals with pulmonary hypertension and FDA-approved therapies."
}